Suchergebnisse - "Ritonavir"

PubPharm (381)

1

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1 : week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

enthalten in: The lancet. HIV | 2024

von Orkin, C. | Molina, J. | Cahn, P. | +112

2

A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance

enthalten in: The Journal of antimicrobial chemotherapy | 2024

von Abdullahi, A. | Diaz, A. | Fopoussi, O. | +5

3

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV) : an open-label, phase 2, randomised, controlled, adaptive trial

enthalten in: The Lancet. Infectious diseases | 2024

von Schilling, W. | Jittamala, P. | Watson, J. | +89

ErratumIn: Lancet Infect Dis. 2023 Dec;23(12):e511. - PMID 37839427

4

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children : A Substudy of the CHAPAS-4 Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Waalewijn, H. | Szubert, A. | Wasmann, R. | +18

5

Second-Line Switch to Dolutegravir for Treatment of HIV Infection

enthalten in: The New England journal of medicine | 2023

von Ombajo, L. | Penner, J. | Nkuranga, J. | +12

6

Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12 years and older : a PK substudy of the SMILE trial

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von Abdalla, S. | Compagnucci, A. | Zheng, Y. | +39

7

Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV

enthalten in: AIDS research and human retroviruses | 2022

von Siddiqui, M. | Moore, T. | Long, D. | +6

8

Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir : a DUALIS sub-study

enthalten in: AIDS care | 2022

von Olliges, E. | Bührlen, B. | Fischer, F. | +14

9

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA) : week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

enthalten in: The lancet. HIV | 2022

von Paton, N. | Musaazi, J. | Kityo, C. | +101

CommentIn: Lancet HIV. 2022 Jun;9(6):e368-e369. - PMID 35460602

10

Brief Report : No Differences Between Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297)

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2022

von Shaffer, D. | Kumwenda, J. | Chen, H. | +12

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[39]